Because low-grade serous ovarian carcinoma is relatively resistant to chemotherapy [34], developing GDF15 as a potential serum biomarker to select patients that are sensitive to chemotherapy warrants further investigation. Here, GDF15 is linked to ovarian serous carcinoma.